Cardiogenesis gets transmyocardial laser revascularisation (TMR) trial go-ahead
This article was originally published in Clinica
Cardiogenesis plans to enrol up to 500 patients in a US trial of transmyocardial laser revascularisation (TMR). The company has received an IDE to compare combined bypass surgery and adjunctive TMR with bypass alone in patients who cannot be completely revascularised by surgery, in a randomised, prospective, blinded, multi-centre trial.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.